The Oncology InstituteTOI +6.62%61 Market Cap is $579.9 Mil as of Jul. 07, 2026. GuruFocus rates TOI with a GF Score™ of 61/100 and a GF Value™ of $2.26 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 692 Healthcare Providers & Services companies, The Oncology Institute ranks better than 73.12% on this metric.
The Oncology Institute's quarterly market cap
increased
from Sep. 2025 ($340.5 Mil) to Dec. 2025 ($352.0 Mil) but then
declined
from Dec. 2025 ($352.0 Mil) to Mar. 2026 ($306.9 Mil).
The Oncology Institute's annual market cap
declined
from Dec. 2023 ($151.3 Mil) to Dec. 2024 ($23.4 Mil) but then
increased
from Dec. 2024 ($23.4 Mil) to Dec. 2025 ($352.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. The Oncology Institute's Enterprise Value for Today is $654.5 Mil.
The Oncology Institute (NAS:TOI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, The Oncology Institute's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Market Cap distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
The Oncology Institute's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (TOI) has a Market Cap of $579.9 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #186 out of 692 companies in the Healthcare Providers & Services industry, placing it in the top 26.9%.
Is The Oncology Institute's Market Cap too high?
The Oncology Institute's current Market Cap is $579.9 Mil. The Healthcare Providers & Services industry median Market Cap is 98.60. The Oncology Institute's value of $579.9 Mil is 488.2% above this industry median. Based on the distribution chart, The Oncology Institute ranks #186 out of 692 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, The Oncology Institute has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Market Cap compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #186 out of 692 companies for Market Cap. This puts The Oncology Institute in the upper half of its industry. The industry median Market Cap is 98.60. The Oncology Institute's value of $579.9 Mil is 488.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 98.60, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Oncology Institute's current Market Cap of $579.9 Mil is 488.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on The Oncology Institute and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 98.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current Market Cap is $579.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
Based on GuruFocus' analysis, The Oncology Institute (TOI) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.26, compared to a current price of $5.80 — trading 156.6% above its estimated fair value. The current Market Cap is $579.9 Mil and 488.2% above the Healthcare Providers & Services industry median of 98.60. The Oncology Institute's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For The Oncology Institute (TOI), the current Market Cap is $579.9 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Oncology Institute (TOI) Overvalued in 2026?
Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued.
The current stock price of $5.80 is trading 156.6% above its estimated GF Value™ of $2.26.
GuruFocus considers The Oncology Institute to be Significantly Overvalued.
Key valuation signals for TOI:
Market Cap: $579.9 Mil
GF Value™: $2.26 vs. price of $5.80 (156.6% above fair value)
Industry Position: 488.2% above the Healthcare Providers & Services median (#186 of 692)
No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
61GF Score
Get the complete analysis for TOI
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOI has been successfully added to your 
